China XLX Fertiliser
2021 Interim Results Highlights:
- Achieved revenue of approximately RMB 7,573 million, rising by 53% Y-O-Y.
- Revenue derived from the sales of urea increased by 32% Y-O-Y to approximately RMB2,074 million. Gross profit margin of urea increased to approximately 35.4% from approximately 26.8% last year.
- The unaudited total comprehensive income attributable to the owners of the parent increased significantly by 259% to approximately RMB646 million for 1H2021. Earnings per share reached 55.1 RMB cents in 1H2021.
HONG KONG / ACCESSWIRE / August 9, 2021 / China XLX Fertiliser Ltd. ("China XLX" or the "Company", together with its subsidiaries collectively known as the "Group") (HKSE:01866.HK) announced the interim results o for the six months ended 30 June 2021 (the "Period"). The Group recorded a revenue of approximately RMB7,573 million, increased by 53% from the same period last year. Gross profit increased sharply by 99.4% to approximately RMB2,118 million. Profit for the period surged by 237% to approximately RMB 889 million from last year. The comprehensive income attributable to owners of the parent company jumped by 259% to approximately RMB646 million, as compared with the same time last year.
In the first half of 2021, the recovery of the domestic fertilisers and chemical products market has accelerated. With the Group's third production base in Jiangxi Jiujiang successfully commissioned in February 2021, total production capacity reached new height, further solidifying geographical coverage, forming Central, Northwest and Southeast three strategic production bases in the PRC.
With the Jiujiang production base put into production, the market share of the Group has increased and its cost advantage has been further enhanced. Additionally, the rising global food price and increasing demand further boosted the sales of key products of the Group, contributing to satisfying results for 1H2021. Revenue derived from the sales of urea increased by 32% to approximately RMB2,074 million. The leap was mainly due to the increase in sales volume and the average selling price of urea products of the Group by approximately 8% and 23% Y-O-Y, respectively. Gross profit margin of urea of the Group increased to approximately 35.4% for 1H2021 from approximately 26.8% for 1H2020.
Strong results have also been recorded in the businesses of compound fertilisers and methanol. Revenue derived from the sales of compound fertilisers increased by 13% to approximately RMB1,981 million for 1H2021, mainly due to the increase in sales volume and average selling price of compound fertilisers by approximately 5% and 8% respectively. Revenue derived from the sales of methanol was up by 355% to approximately RMB733 million for 1H2021. The increased sales of methanol were a result of the increase in average selling price and sales volume of methanol of the Group by 57% and 190% YoY respectively. The increased sales volume was mainly contributed by the additional production capacity of the third production base in Jiujiang. Due to the rebound in international energy prices which in turn boosted the average selling price of methanol, gross profit margin of methanol of the Group rose by approximately 22 percentage points to approximately 19.7% for 1H2021.
Revenue derived from the sales of Dimethyl Ether (DME) rose by 79% to approximately RMB618 million for 1H2021. Revenue derived from the sales of melamine increased largely by 69% to approximately RMB535 million for 1H2021. Revenue derived from the sales of furfuryl alcohol products was up by 48% to approximately RMB335 million for 1H2021. The revenue from the sales of urea solution for vehicle reached approximately RMB236 million for 1H2021, due to product structure adjustment.
Looking ahead, Mr. Liu Xingxu, Chairman of China XLX, said that with the introduction of the new agricultural reform policies and the "dual-carbon" policies, the acceleration of elimination of the backward production capacity and emphasis on the high-quality and efficient green development of the agriculture industry would be beneficial to the development of industry leaders. The Group adheres to the strategy of green, low carbon and sustainable development in terms of production, R&D or product innovation, which will provide favourable conditions for consolidating the main fertilisers industry. In addition, the chemical product market is affected by rising international energy prices, strong downstream demand, and the business cycle of chemical product prices will continue at a high level. Each of the Group's chemical product can meet the various needs of its downstream users. On the basis of consolidating the competitive advantages of our existing chemical products, the Group would be committed to extending the development of the industrial chain. As new products continue to be put into production, it will definitely further enhance the Group's profitability and market competitiveness.
Since the Jiujiang production base has been put into production, the market share of the Group has increased and its cost advantage has been further enhanced. The Group will leverage its three major production bases to strengthen its competitive advantage of "low-cost and differentiation" and widen its business horizon. Being committed to leading the industry as "Pioneer of High-Efficiency Fertilisers in China" to lead the industry with higher standard and support the industry's continuous exploration in high efficiency fertiliser and scientific agriculture, the Group strives to reward farmers and serve the community with higher standards, and to make higher contribution to China agriculture.
~END~
About China XLX Fertiliser Ltd.
China XLX Fertiliser Ltd. is one of the largest and most cost-efficient coal-based urea producers in China. The Group is principally engaged in developing, manufacturing, and selling of related differentiated products such as urea, compound fertiliser, methanol, dimethyl ether, melamine, furfuryl alcohol, furfural, 2-methylfuran and pharmaceutical intermediates. Adhering to the competitive strategy of combination of "comprehensive cost control and product differentiation", the Group aims at further development of the fertiliser industry as a whole. Boasting resources of its Henan, Xinjiang, Jiujiang bases, the Group strives to expand its business into various upstream product lines including new energy, new chemical materials, and coal chemicals. The Group is committed to becoming the most respected enterprise in the chemical fertilisers industry. The Company's shares are traded on the main board of the Stock Exchange of Hong Kong Limited (stock code: 01866.HK).
Investor and Media Enquiries
China XLX Fertiliser Ltd.
GUI, Lin
Tel: 86-135 6942 3415
Email: lin.gui@chinaxlx.com.hk
PRChina Limited
Joanne Liu/ Jack Liu/ Rachel Xia
Tel: 852-2522 1368 / 852-2522 1838
Email: jjyliu@prchina.com.hk
zyliu@prchina.com.hk
rxia@prchina.com.hk
SOURCE: China XLX Fertiliser
View source version on accesswire.com:
https://www.accesswire.com/658898/China-XLX-Announces-2021-Interim-Results-Strong-and-Solid-Recovery-with-NP-Surging-by-259
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release
Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres
General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release
DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
GA-ASI Completes Full-Scale Fatigue Test on MQ-9B17.11.2025 03:10:00 CET | Press release
MQ-9B's Third Lifetime Test Completes the FSF Testing Process With a Total of 120,000 Hours DUBAI, UAE / ACCESS Newswire / November 16, 2025 / On October 31, 2025, General Atomics Aeronautical Systems, Inc. (GA-ASI) completed its "third lifetime" of full-scale fatigue (FSF) testing for the MQ-9B Remotely Piloted Aircraft (RPA). Completion of FSF testing for the third and final lifetime includes a total of 120,000 operating hours (40,000+ flight hours per aircraft life) for the RPA and is a key milestone in validating the design of the airframe. The testing verifies the airframe structural integrity in support of certification to the NATO STANAG 4671 standard. The aim of the testing is to identify any potential structural deficiencies ahead of fleet usage and assist in developing inspection and maintenance schedules for the airframe. Test results will be used as documentation for certification and will form the basis for in-service inspections of structural components. "The completion o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
